IDENTIFICATION OF KEY TARGET GENES AND
PATHWAY ANALYSIS IN NONALCOHOLIC FATTY LIVER
DISEASE VIA INTEGRATED BIOINFORMATICS ANALYSIS
Chen X.1, Zhang L.2, Wang Y.1, Li R.1, Yang M.1, Gao L.3*
*Corresponding Author: Lei Gao, MD, College of Basic Medicine, Changchun University of Chinese
Medicine, 1035 Boshuo, Road, Jingyue District, Changchun City, Jilin Province, 130117, China;
Tel:+ 86-431-8604 5309, Email: gaolei790708@163.com
page: 10
|
|
REFERENCES
1. Erman H, Beydogan E, Cetin SI, Boyuk B. Endocan:
A Biomarker for Hepatosteatosis in Patients with
Metabolic Syndrome. Mediators Inflamm. 2020;
2020: 3534042.
2. Aizawa M, Inagaki S, Moriyama M, Asano K, Kakehashi
M. Modeling the natural history of fatty liver
using lifestyle-related risk factors: Effects of body
mass index (BMI) on the life-course of fatty liver.
PLoS One. 2019; 14(10):e0223683.
3. Zelber-Sagi S, Lotan R, Shlomai A, Webb M, Harrari
G, Buch A, et al. Predictors for incidence and remission
of NAFLD in the general population during a seven-year prospective follow-up. Journal of hepatology.
2012; 56(5): 1145-1151.
4. Sookoian S, Pirola CJ. Review article: shared disease
mechanisms between non-alcoholic fatty liver
disease and metabolic syndrome - translating knowledge
from systems biology to the bedside. Aliment
Pharmacol Ther. 2019; 49(5): 516-527.
5. Friedman SL, Neuschwander-Tetri BA, Rinella M,
Sanyal AJ. Mechanisms of NAFLD development and
therapeutic strategies. Nat Med. 2018; 24(7):908-922.
6. Rinella ME. Nonalcoholic fatty liver disease: a systematic
review. JAMA. 2015; 313(22):2263-73.
7. Noureddin M, Rinella ME. Nonalcoholic Fatty liver
disease, diabetes, obesity, and hepatocellular carcinoma.
Clin Liver Dis. 2015; 19(2):361-79.
8. Fabbrini E, Magkos F, Mohammed BS, Pietka T,
Abumrad NA, Patterson BW, et al. Intrahepatic
fat, not visceral fat, is linked with metabolic complications
of obesity. Proc Natl Acad Sci USA.
2009;106(36):15430-5.
9. Konerman MA, Jones JC, Harrison SA. Pharmacotherapy
for NASH: Current and emerging. J Hepatol.
2018; 68(2):362-375.
10. Sookoian S, Rosselli MS, Gemma C, Burgueño AL,
Fernández Gianotti T, Castaño GO, Pirola CJ. Epigenetic
regulation of insulin resistance in nonalcoholic
fatty liver disease: impact of liver methylation of the
peroxisome proliferator-activated receptor γ coactivator
1α promoter. Hepatology. 2010; 52(6):1992-2000
11. Liu NK, Xu XM. MicroRNA in central nervous
system trauma and degenerative disorders. Physiol
Genomics. 2011; 43(10):571-80
12. Piazzolla VA, Mangia A. Noninvasive Diagnosis of
NAFLD and NASH. Cells. 2020; 9(4):1005
13. Zou B, Yeo YH, Nguyen VH, Cheung R, Ingelsson E,
Nguyen MH. Prevalence, characteristics and mortality
outcomes of obese, nonobese and lean NAFLD
in the United States, 1999-2016. J Intern Med. 2020;
288(1):139-151
14. Lefebvre P, Lalloyer F, Baugé E, Pawlak M, Gheeraert
C, Dehondt H, et al. Interspecies NASH disease activity
whole-genome profiling identifies a fibrogenic
role of PPARα-regulated dermatopontin. JCI Insight.
2017 Jul 6;2(13):e92264
15. Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev
D, Evangelista C, et al. NCBI GEO: mining tens of
millions of expression profiles--database and tools
update. Nucleic Acids Res. 2007; 35(Database
issue):D760-5
16. Braschi B, Denny P, Gray K, Jones T, Seal R,
Tweedie S, et al. Genenames.org: the HGNC and
VGNC resources in 2019. Nucleic Acids Res. 2019;
47(D1):D786-D792
17. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi
W, Smyth GK. limma powers differential expression
analyses for RNA-sequencing and microarray studies.
Nucleic Acids Res. 2015; 43(7):e47
18. Wang L, Cao C, Ma Q, Zeng Q, Wang H, Cheng Z, et
al. RNA-seq analyses of multiple meristems of soybean:
novel and alternative transcripts, evolutionary and functional
implications. BMC Plant Biol. 2014; 14:169
19. Bonow RO. Braunwald`s Heart Disease: A Textbook of
Cardiovascular Medicine, Single Volume, 9th Edition.
20. Szekely, G., Rizzo, M. Hierarchical Clustering via
Joint Between-Within Distances: Extending Ward’s
Minimum Variance Method. Journal of Classification;
2005; 22, 151–183
21. Huang da W, Sherman BT, Lempicki RA. Systematic
and integrative analysis of large gene lists using
DAVID bioinformatics resources. Nat Protoc. 2009;
4(1):44-57
22. Huang da W, Sherman BT, Lempicki RA. Bioinformatics
enrichment tools: paths toward the comprehensive
functional analysis of large gene lists. Nucleic
Acids Res. 2009; 37(1):1-13
23. Huang Z, Shi J, Gao Y, Cui C, Zhang S, Li J, et al.
HMDD v3.0: a database for experimentally supported
human microRNA-disease associations. Nucleic Acids
Res. 2019; 47(D1):D1013-D1017
24. Paraskevopoulou MD, Vlachos IS, Karagkouni D,
Georgakilas G, Kanellos I, Vergoulis T, et al. DIANA-
LncBase v2: indexing microRNA targets on
non-coding transcripts. Nucleic Acids Res. 2016;
44(D1):D231-8
25. Li JH, Liu S, Zhou H, Qu LH, Yang JH. StarBase
v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA
and protein-RNA interaction networks from largescale
CLIP-Seq data. Nucleic Acids Res. 2014;
42(Database issue):D92-7
26. Thorn CF, Klein TE, Altman RB. PharmGKB: the
pharmacogenetics and pharmacogenomics knowledge
base. Methods Mol Biol. 2005; 311:179-91
27. Chen HJ, Liu J. Actein ameliorates hepatic steatosis
and fibrosis in high fat diet-induced NAFLD by
regulation of insulin and leptin resistant. Biomed
Pharmacother. 2018; 97: 1386-1396.
28. Pan X, Zheng M, Zou T, Liu W, Gu X, Zhang X, et
al. The LEPR K109R and Q223R Might Contribute to the Risk of NAFLD: A Meta-Analysis. Curr Mol
Med. 2018; 18(2): 91-99.
29. Zhang Y, Xiang D, Hu X, Ruan Q, Wang L, Bao Z.
Identification and study of differentially expressed
miRNAs in aged NAFLD rats based on high-throughput
sequencing. Ann Hepatol. 2020; 19(3):302-312
30. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D,
Pennacchio LA, et al. Genetic variation in PNPLA3
confers susceptibility to nonalcoholic fatty liver disease.
2008; 40(12): 1461-1465.
31. Kozlitina J, Smagris E, Stender S, Nordestgaard BG,
Cohen JCJNG. Exome-wide association study identifies
a TM6SF2 variant that confers susceptibility to
nonalcoholic fatty liver disease. 2014; 46(4): 352-356.
32. Mancina RM, Dongiovanni P, Petta S, Pingitore P,
Meroni M, Rametta R, et al. The MBOAT7-TMC4
Variant rs641738 Increases Risk of Nonalcoholic
Fatty Liver Disease in Individuals of European Descent.
2016; 150(5): 1219-1230.e1216.
33. Eslam M, Hashem AM, Leung R, Romero-Gomez
M, Berg T, Dore GJ, et al. ; International Hepatitis
C Genetics Consortium (IHCGC). Interferon-λ
rs12979860 genotype and liver fibrosis in viral and
non-viral chronic liver disease. Nat Commun. 2015;
6:6422.
34. Petta S, Valenti L, Marra F, Grimaudo S, Tripodo C,
Bugianesi E, et al. MERTK rs4374383 polymorphism
affects the severity of fibrosis in non-alcoholic fatty
liver disease. 2016; 64(3): 682-690.
35. Aller R, De Luis DA, Izaola O, González Sagrado M,
Conde R, Pacheco D, et al. Lys656Asn polymorphism
of leptin receptor, leptin levels and insulin resistance
in patients with non alcoholic fatty liver disease. Eur
Rev Med Pharmacol Sci. 2012;16(3):335-41.
36. An BQ, Lu LL, Yuan C, Xin YN, Xuan SY. Leptin
Receptor Gene Polymorphisms and the Risk of Non-
Alcoholic Fatty Liver Disease and Coronary Atherosclerosis
in the Chinese Han Population. Hepat Mon.
2016; 16(4):e35055.
37. Neville LF, Mathiak G, Bagasra O. The immunobiology
of interferon-gamma inducible protein 10 kD
(IP-10): a novel, pleiotropic member of the C-X-C
chemokine superfamily. Cytokine Growth Factor
Rev. 1997; 8(3):207-19.
38. Luster AD, Unkeless JC, Ravetch JV. Gamma-interferon
transcriptionally regulates an early-response
gene containing homology to platelet proteins. Nature.
1985; 315(6021):672-6.
39. Bertola A, Bonnafous S, Anty R, Patouraux S, Saint-
Paul MC, Iannelli A, et al. Hepatic expression patterns
of inflammatory and immune response genes
associated with obesity and NASH in morbidly obese
patients. PLoS One. 2010; 5(10):e13577.
40. Zhang X, Shen J, Man K, Chu ES, Yau TO, Sung
JC, et al. CXCL10 plays a key role as an inflammatory
mediator and a non-invasive biomarker of
non-alcoholic steatohepatitis. Journal of hepatology.
2014; 61(6): 1365-1375.
41. Dong XC, Copps KD, Guo S, Li Y, Kollipara R, Depinho
RA, et al. Inactivation of Hepatic Foxo1 by
Insulin Signaling Is Required for Adaptive Nutrient
Homeostasis and Endocrine Growth Regulation.
2008; 8(1): 0-76.
42. Munekata K, Sakamoto K. Forkhead transcription
factor Foxo1 is essential for adipocyte differentiation.
In Vitro Cell Dev Biol Anim. 2009; 45(10):642-51.
43. Li Y, Ma Z, Jiang S, Hu W, Li T, Di S, et al. A global
perspective on FOXO1 in lipid metabolism and lipidrelated
diseases. Prog Lipid Res. 2017; 66: 42-49.
44. Xin Z, Ma Z, Hu W, Jiang S, Yang Z, Li T, et al.
FOXO1/3: Potential suppressors of fibrosis. Ageing
Res Rev. 2018; 41: 42-52.
45. Valenti L, Dongiovanni P, Rametta R, Fracanzani
AL, Fargion SJD, Disease L. FOXO1 genotype influences
the susceptibility to and severity of NAFLD by
modulating FOXO1 expression. 2009; 41(3):A2–A3.
|
|
|
|
 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
